Reboxetine

• CAT Number: I035473
• CAS Number: 71620-89-8
• Molecular Formula: C19H23NO3
• Molecular Weight: 313.39
• Purity: 98%
• Synonyms: Reboxetine; Vestra
• Solubility: Soluble in DMSO
• Appearance: Solid powder
• Storage: Dry, dark and at 0 - 4℃ for short term (days to weeks) or -20℃ for long term (months to years).
• IUPAC Name: (R)-2-((R)-(2-ethoxyphenoxy)(phenyl)methyl)morpholine
• InChI: InChI=1S/C19H23NO3/c1-2-21-16-10-6-7-11-17(16)23-19(15-8-4-3-5-9-15)18-14-20-12-13-22-18/h3-11,18-20H,2,12-14H2,1H3/t18-,19-/m1/s1
• InChIKey: CBQGYUDMJHNJBX-RTBURBONSA-N
• SMILES: CCOc1c(O[C@H](c2ccccc2)[C@H]3CNCCO3)cccc1

Reboxetine (Cat.No:I035473) is a potent antidepressant that prevents clonidine-induced hypothermia in mice. It is a selective norepinephrine reuptake inhibitor.

Reference

1: Popławska M, Wróblewska D, Borowicz KK. Interactions between an antidepressant reboxetine and four classic antiepileptic drugs in the mouse model of myoclonic seizures. Pharmacol Rep. 2015 Dec;67(6):1141-6. doi: 10.1016/j.pharep.2015.04.016. Epub 2015 May 9. PubMed PMID: 26481533.
2: Hughes S, Hickey L, Donaldson LF, Lumb BM, Pickering AE. Intrathecal reboxetine suppresses evoked and ongoing neuropathic pain behaviours by restoring spinal noradrenergic inhibitory tone. Pain. 2015 Feb;156(2):328-34. doi: 10.1097/01.j.pain.0000460313.73358.31. PubMed PMID: 25599454.
3: Borowicz KK, Zarczuk R, Latalski M, Borowicz KM. Reboxetine and its influence on the action of classical antiepileptic drugs in the mouse maximal electroshock model. Pharmacol Rep. 2014 Jun;66(3):430-5. doi: 10.1016/j.pharep.2013.11.009. Epub 2014 Apr 13. PubMed PMID: 24905519.
4: Ghanizadeh A. A systematic review of reboxetine for treating patients with attention deficit hyperactivity disorder. Nord J Psychiatry. 2015 May;69(4):241-8. doi: 10.3109/08039488.2014.972975. Epub 2014 Nov 21. Review. PubMed PMID: 25415763.
5: Roni MA, Rahman S. Effects of lobeline and reboxetine, fluoxetine, or bupropion combination on depression-like behaviors in mice. Pharmacol Biochem Behav. 2015 Dec;139(Pt A):1-6. doi: 10.1016/j.pbb.2015.10.006. Epub 2015 Oct 9. PubMed PMID: 26455278.
6: Lundmark E, Stenberg A, Hägglöf B, Nevéus T. Reboxetine in therapy-resistant enuresis: A randomized placebo-controlled study. J Pediatr Urol. 2016 Dec;12(6):397.e1-397.e5. doi: 10.1016/j.jpurol.2016.04.048. Epub 2016 Jul 12. PubMed PMID: 27544904.
7: Wiles NJ, Fischer K, Cowen P, Nutt D, Peters TJ, Lewis G, White IR. Allowing for non-adherence to treatment in a randomized controlled trial of two antidepressants (citalopram versus reboxetine): an example from the GENPOD trial. Psychol Med. 2014 Oct;44(13):2855-66. doi: 10.1017/S0033291714000221. Epub 2014 Mar 3. PubMed PMID: 25065692; PubMed Central PMCID: PMC4131263.
8: Gray VC, Hughes RN. Drug-, dose- and sex-dependent effects of chronic fluoxetine, reboxetine and venlafaxine on open-field behavior and spatial memory in rats. Behav Brain Res. 2015 Mar 15;281:43-54. doi: 10.1016/j.bbr.2014.12.023. Epub 2014 Dec 16. PubMed PMID: 25523028.
9: Dong C, Zhang JC, Yao W, Ren Q, Yang C, Ma M, Han M, Saito R, Hashimoto K. Effects of escitalopram, R-citalopram, and reboxetine on serum levels of tumor necrosis factor-α, interleukin-10, and depression-like behavior in mice after lipopolysaccharide administration. Pharmacol Biochem Behav. 2016 May;144:7-12. doi: 10.1016/j.pbb.2016.02.005. Epub 2016 Feb 15. PubMed PMID: 26892759.
10: Bhagya V, Srikumar BN, Raju TR, Shankaranarayana Rao BS. The selective noradrenergic reuptake inhibitor reboxetine restores spatial learning deficits, biochemical changes, and hippocampal synaptic plasticity in an animal model of depression. J Neurosci Res. 2015 Jan;93(1):104-20. doi: 10.1002/jnr.23473. Epub 2014 Aug 21. PubMed PMID: 25146499.
11: Penmatsa A, Wang KH, Gouaux E. X-ray structures of Drosophila dopamine transporter in complex with nisoxetine and reboxetine. Nat Struct Mol Biol. 2015 Jun;22(6):506-508. doi: 10.1038/nsmb.3029. Epub 2015 May 11. PubMed PMID: 25961798; PubMed Central PMCID: PMC4608549.
12: Arias HR, Fedorov NB, Benson LC, Lippiello PM, Gatto GJ, Feuerbach D, Ortells MO. Functional and structural interaction of (-)-reboxetine with the human α4β2 nicotinic acetylcholine receptor. J Pharmacol Exp Ther. 2013 Jan;344(1):113-23. doi: 10.1124/jpet.112.197905. Epub 2012 Sep 25. PubMed PMID: 23010362.
13: Gibbs AA, Bautista CE, Mowlem FD, Naudts KH, Duka DT. Catechol-O-methyltransferase val158met genotype determines effect of reboxetine on emotional memory in healthy male volunteers. J Psychiatry Neurosci. 2014 May;39(3):E24-31. PubMed PMID: 24467942; PubMed Central PMCID: PMC3997609.
14: Kruchinina AD, Gengin MT. [Effect of reboxetine on activity of carboxypeptidase E in the nerve tissue of rats]. Biomed Khim. 2015 Sep-Oct;61(5):657-60. doi: 10.18097/PBMC20156105657. Russian. PubMed PMID: 26539877.
15: Graf H, Wiegers M, Metzger CD, Walter M, Grön G, Abler B. Erotic stimulus processing under amisulpride and reboxetine: a placebo-controlled fMRI study in healthy subjects. Int J Neuropsychopharmacol. 2014 Oct 31;18(2). pii: pyu004. doi: 10.1093/ijnp/pyu004. PubMed PMID: 25612894; PubMed Central PMCID: PMC4368880.
16: Caudill MM, Hunter AM, Cook IA, Leuchter AF. The Antidepressant Treatment Response Index as a Predictor of Reboxetine Treatment Outcome in Major Depressive Disorder. Clin EEG Neurosci. 2015 Oct;46(4):277-84. doi: 10.1177/1550059414532443. Epub 2014 Sep 24. PubMed PMID: 25258429.
17: Metzger CD, Wiegers M, Walter M, Abler B, Graf H. Local and Global Resting State Activity in the Noradrenergic and Dopaminergic Pathway Modulated by Reboxetine and Amisulpride in Healthy Subjects. Int J Neuropsychopharmacol. 2015 Jul 25;19(2). pii: pyv080. doi: 10.1093/ijnp/pyv080. PubMed PMID: 26209860; PubMed Central PMCID: PMC4772816.
18: Poyurovsky M, Fuchs C, Pashinian A, Levi A, Weizman R, Weizman A. Reducing antipsychotic-induced weight gain in schizophrenia: a double-blind placebo-controlled study of reboxetine-betahistine combination. Psychopharmacology (Berl). 2013 Apr;226(3):615-22. doi: 10.1007/s00213-012-2935-2. Epub 2012 Dec 13. PubMed PMID: 23239133.
19: Amrami-Weizman A, Maayan R, Gil-Ad I, Pashinian A, Fuchs C, Kotler M, Poyurovsky M. The effect of reboxetine co-administration with olanzapine on metabolic and endocrine profile in schizophrenia patients. Psychopharmacology (Berl). 2013 Nov;230(1):23-7. doi: 10.1007/s00213-013-3199-1. Epub 2013 Jul 5. PubMed PMID: 23828160.
20: Bruno A, Zoccali R, Bellinghieri PM, Pandolfo G, De Fazio P, Spina E, Muscatello MR. Reboxetine adjuvant therapy in patients with schizophrenia showing a suboptimal response to clozapine: a 12-week, open-label, pilot study. J Clin Psychopharmacol. 2014 Oct;34(5):620-3. doi: 10.1097/JCP.0000000000000196. PubMed PMID: 25118083.